

This is an overview about all ongoing clinical trials of the CCCA and the cooperating network partners.

To find the right contact person, please orientate yourself here at the respective study and the named study site. >>[Detailed contact information can then be found at 'ISCO | Contact Information'](#).

Skin Cancer		
Indication	Study	Study site
Melanoma	NIVO-PASS Pattern of use and safety/effectiveness of Nivolumab in routine oncology practice.	UKA Dept. of Dermatology
Melanoma	NIS-NICO A national, prospective, non-interventional study (NIS) of Nivolumab monotherapy or in combination with Ipilimumab in patients with advanced melanoma and in Patients with adjuvant Nivolumab therapy.	UKA Dept. of Dermatology
Melanom Stad. II	NivoMela Adjuvant Nivolumab Treatment of Stage II Melanoma at High Risk of Recurrence. A randomized, controlled, phase III clinical trial with biomarker-based risk stratification	UKA Dept. of Dermatology
Malignant melanoma	ADOREG Nationwide prospective registry for health services research in dermatologic oncology Indication: malignant melanoma from stage IIB, epithelial skin tumors, actinic keratosis.	UKA Dept. of Dermatology
Advanced, metastasized melanoma	IO102-IO103-013 (IOB-013) A phase 3, open-label, randomized, clinical trial of IO102-IO103 in combination with Pembrolizumab versus Pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma.	UKA Dept. of Dermatology
completely resected high-risk Melanoma	R3767-ONC-2055 A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected high-risk Melanoma	UKA Dept. of Dermatology

<p>BRAFV600-mutated melanoma</p>	<p>Bering Melanoma Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interentional study in Germany and Austria.</p>	<p>UKA Dept. of Dermatology</p>
<p>CSCC</p>	<p>CemiSkin Registry study with two cohorts for patients with advanced CSCC treated with Cemiplimab or other approaches.</p>	<p>UKA Dept. of Dermatology</p>
<p>Merkel cell carcinoma</p>	<p>MCC-Trim Noninterventional cohort registry study to assess characteristics and management of patients with merkel cell carcinoma in Germany.</p>	<p>UKA Dept. of Dermatology</p>
<p>Basal cell carcinoma, cutaneous squamous cell carcinoma</p>	<p>Philogen PH-L19IL2TNFNMSC-04/19 Patients with locally advanced (non-metastatic, node-negative, single or multifocal) basal cell carcinoma (BCC) or high-risk cutaneous squamous cell carcinoma (cSCC) who are suitable for intratumoral injection, who are not eligible for surgery or radiotherapy based on the assessment of a local multidisciplinary tumor board, or who decline surgery or radiotherapy, and for whom histologic assessment is available according to international guidelines. A phase II study of intratumoral administration of L19IL2/L19TNF in patients with non-melanoma skin cancer who have injectable lesions.</p>	<p>UKA Dept. of Dermatology</p>

Gastrointestinal Cancer/Liver and Pancreatic Cancer		
Indication	Study	Study site
Early gastrointestinal carcinomas	ESD Register Germany: Early carcinomas of the GI tract Endoscopic submucosal dissection of early gastrointestinal tract carcinomas.	UKA Dept. of Internal Medicine III
Colon carcinoma	CIRCULATE Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.	UKA Dept. of Internal Medicine III
Adenoma colon	CURE FTR vs. conventional endoscopic therapy for recurrent or incompletely resected non-lifting colorectal adenomas.	UKA Dept. of Internal Medicine III
Colon, papilla, barret Early carcinomas	KI-Colon/Papille/Barrett Endoscopic detection of early stages of carcinoma using computer-aided diagnosis (CAD) with AI algorithms.	UKA Dept. of Internal Medicine III
Colon cancer and/or renal cell cancer	AAV-AH 01 Ex vivo identification of specific gene vector capsids for tumor-targeted gene therapy with adeno-associated viral vectors.	UKA Dept. of Internal Medicine II
Colorectal carcinoma	BNT000-001 Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Colorectal carcinoma	ColoPredict Plus 2.0 Register Retro and prospective evaluation of the role of MSI and KRAS regarding the prognosis of patients with stage I-III colorectal carcinoma.	Medical center Ostallgäu-Kaufbeuren Medical center Aichach-Friedberg
Colorectal carcinoma	Supportive care trial evaluating the prevalence of malnutrition in centralized care of patients with colorectal carcinoma.	Medical center Ostallgäu-Kaufbeuren

CRC, metastasized	FIRE8 Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of Trifluridine/Tipiracil plus Panitumumab versus Trifluridine/Tipiracil plus Bevacizumab as first-line treatment of metastatic colorectal cancer.	UKA Dept. of Internal Medicine II
CCC/HCC	Jade Clinical research platform on treatment and outcome in patients with hepatocellular or cholangiocellular cancer.	UKA Dept. of Internal Medicine II
Metastatic gastrointestinal cancer	GOBLET A phase 1 / 2 multiple - indication biomarker, safety, and efficacy study in advanced of metastatic gastrointestinal cancers exploring treatment combinations with Pelareorep and a Tezolizumab.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Gastric carcinoma, colorectal carcinoma	Triangle SARIFA Prospective investigation of the SARIFA phenomenon as a prognostic biomarker in patients with colorectal carcinoma or gastric carcinoma	UKA Dept. of Internal Medicine II
Pankreatic cancer, distal bile duct cancer, papillary cancer	PORRIDGE A prospective randomized study comparing intraoperative endoluminal pyloromyotomy with atraumatic pyloric dilatation in the setting of pylorus-preserving duodenohepatojejunostomy in terms of incidence and severity of postoperative delayed gastric emptying.	Dept. of General, Visceral and Transplant Surgery
CCC	IMMUWHY (AIO-HEP-0119/ass) Advanced stage intrahepatic biliary tract cancer (BTC) (A phase II study of immunotherapy with Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer who have Y-90 SIRT therapy as their standard of care).	UKA Dept. of Internal Medicine II
Esophageal adenocarcinoma	PREFER Endoscopic management of patients with T1bNOMO esophageal adenocarcinoma: a prospective multicenter registry study.	UKA Dept. of Internal Medicine III

AEG	RAMIRIS Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastro-esophageal junction, who failed one prior line of palliative chemotherapy.	UKA Dept. of Internal Medicine III
Hematological Neoplasms		
Indication	Study	Study site
ALL	GMALL-Registry and biomaterial bank Biomaterial collection and prospective data collection on diagnosis, treatment and disease progression of adult ALL.	UKA Dept. of Internal Medicine II
ALL	GMALL-EVOLVE A multicentre, randomized trial in adults with de novo PhiladelphiaChromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with Blinatumomab and chemotherapy in optimal responders and to evaluate Blinatumomab before SCT in suboptimal responders	UKA Dept. of Internal Medicine II
AML	AML register and biomaterial database of the Study Alliance Leukemia (SAL) and the AML Cooperative Group (AML-CG).	UKA Dept. of Internal Medicine II
AML	VR-MEDITATE Relaxation exercises in virtual reality.	UKA Dept. of Internal Medicine II
AML	DECIDER-2 Prospective randomized multicenter phase III trial of Decitabine and Venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.	UKA Dept. of Internal Medicine II

AML MDS	PALOMA Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study, phase III.	UKA Dept. of Internal Medicine II
AML, MDS, CMML, MPN (BCR/ABL1-negative), BPDCN	BMS CA055-001 A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Oral-Aza, Onureg) in Subjects with Moderate or Severe Hepatic Impairment Compared with Normal Hepatic Function in Adult Subjects with Myeloid Malignancies	UKA Dept. of Internal Medicine II
CLL	CLL2-BZAG A prospective, open-label, multicenter phase - II trial to evaluate the efficacy and safety of a sequential regimen of Bendamustin followed by Obinutuzumab (GA101), Zanubritinib (BFB-3111) and Venetoclax (ABT-199).	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
CLL	BO43243 A phase IB open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of Mosunetuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.	UKA Dept. of Internal Medicine II
CML	ASC4START (CABL001J12302) A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral Asciminib versus Nilotinib in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.	UKA Dept. of Internal Medicine II
CML	BlastCrisis Register Multicentric prospective and retrospective register study, collecting patient with CML blast crisis diagnosed in Germany and Europe.	UKA Dept. of Internal Medicine II

DLBCL	<p>DALY 2 EU</p> <p>A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.</p>	UKA Dept. of Internal Medicine II
DLBCL	<p>ARCHED/GLA 2022-1</p> <p>A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma</p>	UKA Dept. of Internal Medicine II
Relapsed aggressive lymphoma	<p>GOAL II</p> <p>A prospective, multicenter randomized phase II trial investigating Gemcitabine / Oxaliplatin / Rituximab with or without Mor208 for patients with relapsed /refractory aggressive lymphoma.</p>	UKA Dept. of Internal Medicine II
Non-Hodgkin Lymphoma	<p>CHARLY</p> <p>Phase-II study on the value of post-transplant cyclophosphamide after haplo-identical stem cell transplantation for poor-risk non-Hodgkin lymphoma (CHARLY Trial).</p>	UKA Dept. of Internal Medicine II
MDS	<p>SELECT-MDS-1</p> <p>A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome Protocol Number: SY-1425-301</p>	UKA Dept. of Internal Medicine II
Multiple myeloma	<p>AlloRelapseMM</p> <p>Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after first-line therapy.</p>	UKA Dept. of Internal Medicine II

Multiple myeloma	GMMG-HD8/DSMM XIX A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma	UKA Dept. of Internal Medicine II
Myeloid neoplasms	GSG-MPN-Registerstudy German MPN-Registry for BCR-ABL1-negative myeloid neoplasms.	UKA Dept. of Internal Medicine II
Myelofibrosis	TRANSFORM-2 Randomized, open-label, phase 3 trial comparing the efficacy and safety of Navitoclax in combination with Ruxolitinib against standard therapy in relapsed/refractory myelofibrosis.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
PCNSL	OptiMATE Optimizing MATRix as remission induction in PCNSL: deescalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III Trial.	UKA Dept. of Internal Medicine II
PCNSL	PRIMA-CNS Age-adjusted high-dose chemotherapy followed by Auto-SCT or conventional chemotherapy with R-MP as first-line treatment in elderly CNS lymphoma patients – a randomized phase III trial	UKA Dept. of Internal Medicine II
GcHD-Prophylaxis after alloHSZT	GRAPPA “ <u>G</u> raft vs Host Disease <u>P</u> rophylaxis in unrelated donor transplantation: a randomized clinical trial comparing <u>P</u> TCY vs <u>A</u> TG” (GRAPPA).	UKA Dept. of Internal Medicine II
Allogeneic transplant patients	PHOEBUS (MPOH08) A multi-center randomized, double blind phase IIb trial evaluating oral pooled fecal microbiotherapie MaaT033 to prevent allogeneic hematopoietic cell transplantation complications	UKA Dept. of Internal Medicine II
Head and Neck Cancer		
Indication	Study	Study site

Parotideal tumors	Study to evaluate the incidence of parotideal tumors and current therapeutic options.	Dept. of Otorhinolaryngology
Sinunasal squamous cell carcinoma	SentiNose Pilot A prospective study to evaluate the safety and feasibility of sentinel lymph node biopsy for sinunasal squamous cell carcinoma without clinical lymph node metastasis.	UKA Dept. of Otorhinolaryngology

Lung and Thoracic Cancer		
--------------------------	--	--

Indication	Study	Study site
NSCLC	Beamion LUNG (BI 1479-0001) An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.	UKA Dept. of Internal Medicine II
NSCLC metastatic to the brain	Break B5 A prospective phase II, open-label, multi-center trial of combined Nivolumab, Ipilimumab and Bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain.	UKA Dept. of Internal Medicine II
NSCLC oligometastatic	BZKF sOMD Biomarker analysis in patients with non-small cell lung cancer at the stage of oligometastasis at the time of initial diagnosis.	UKA Dept. of Internal Medicine II

Breast and Gynecological Cancer		
---------------------------------	--	--

Indication	Study	Study site
Breast Cancer (adjuvant/palliativ)	Praegnant Prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/metastatic setting; health care research, pharmacogenomics, biomarkers, health economics.	Dept. of Gynecology and Obstetrics

Breast cancer (adjuvant)	<p>Tropion-Breast 03</p> <p>A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)</p>	Dept. of Gynecology and Obstetrics
Breast cancer (neoadjuvant)	<p>TRIO-048</p> <p>An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting</p>	Dept. of Gynecology and Obstetrics
Breast cancer (neoadjuvant)	<p>Olympia N</p> <p>A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer (OlympiaN)</p>	Dept. of Gynecology and Obstetrics
Breast cancer advanced/metastatic	<p>CAPTOR</p> <p>Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients</p>	Dept. of Gynecology and Obstetrics
Breast cancer advanced/metastatic	<p>MINVERA</p> <p>Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management. The MINERVA Trial - A phase IV Trial</p>	Dept. of Gynecology and Obstetrics

Breast cancer	<p>SerMa:</p> <p>Prospective, interventional, multicenter non-AMG/MPG study to detect possible markers for prediction of cancer risk and risk assessment of a breast seroma after skin-sparing mastectomy and implant breast reconstruction.</p>	Dept. of Gynecology and Obstetrics
Breast cancer	<p>WAVES</p> <p>Mutual patient-doctor exchange in breast cancer care with the aim of jointly developing new patient-oriented structures.</p>	Dept. of Gynecology and Obstetrics
Breast cancer	<p>Astefania:</p> <p>A phase III, randomized, double blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant Atezolizumab or placebo and Trastuzumab Emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy.</p>	Dept. of Gynecology and Obstetrics
Breast cancer	<p>AXSANA</p> <p>(Axillary Surgery After NeoAdjuvant Treatment) prospective, multicenter registry study evaluating different guideline-compliant surgical procedures in the axilla (sentinel node biopsy, targeted axillary dissection, axillary dissection) after neoadjuvant chemotherapy.</p>	Dept. of Gynecology and Obstetrics
Breast cancer	<p>EUBREAST-01</p> <p>Omission of sentinel lymph node biopsy in triple-negative and HER2- positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial.</p>	<p>Hematological oncological practice Heinrich, M.D./Bangerter, M.D.</p> <p>Dept. of Gynecology and Obstetrics</p>
Breast cancer	<p>NeoMono</p> <p>An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab - CTX therapy.</p>	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.

Breast cancer	DESTINY A phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in subjects with high-risk Her2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	ADAPTlate A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker - adjusted personalized therapy. Comparison of the combination of Abemaciclib plus standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+ / HER2- early breast cancer.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	SASCIA Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	BrandO-Bio Registry trial evaluating the biologic disease profile and the clinical course in breast and ovarian cancer patients.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer Detectable ESR1 Mutation	SERENA-6: A Phase III, double - blind, randomised study to assess. Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6. Inhibitor (Palbociclib or Abemaciclib) vs continuing aromatase Inhibitor. (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC. Patients with detectable ESR1 mutation without disease progression. During 1L treatment with AI + CDK4/6 Inhibitor.	Dept. of Gynecology and Obstetrics
Breast cancer	OMCAT Development of an artificial intelligence-based incident prediction algorithm to improve cancer patient care and patient safety	Dept. of Gynecology and Obstetrics

Breast Cancer	PRISMA Primary hormone-sensitive breast cancer: optimizing care on demand through a patient-centered, digital application	Dept. of Gynecology and Obstetrics
Breast cancer (palliativ)	PreCycle Therapy with Palbociclib and Letrozole or Palbociclib and Fulvestrant.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	OLIGOMA Randomized, multinational, multicenter testing of the effectiveness and tolerability of ocalradiotherapy of metastases as a supplement to standard therapy in patients with oligometastatic breast cancer.	Dept. of Gynecology and Obstetrics
Endometrial cancer	ECLAT: Pelvic and paraaortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence. A multicenter prospective randomized controlled trial.	Dept. of Gynecology and Obstetrics
Ovarian cancer	CAROLIN: Characteristics related to assessments of disease, patient and treatment associated with long-term survival in ovarian cancer patients (CAROLIN) - Intergroup study NOGGO / A-AGO.	Dept. Of Gynecology and Obstetrics
Ovarian cancer	SCOUT-1 Prospective non-interventional observational study to collect clinical and patient-reported data from the daily routine of patients with ovarian cancer eligible for platinum-based first-line chemotherapy and scheduled for BCRA/HRD testing.	Dept. Of Gynecology and Obstetrics
Vulvar intraepithelial neoplasia	DeIVIN A multicenter phase I trial evaluating the safety and preliminary efficacy of local Decitabine treatment of human papillomavirus (HPV)-induced vulvar intraepithelial neoplasia (VIN) grade 2/3.	Dept. of Gynecology and Obestrics

Sarcoma		
Indication	Study	Study site
Osteosarcoma	COSS - Register Clinical registry for children, adolescents, and adults with osteosarcoma and biologically related bone tumors of the cooperative osteosarcoma study group.	UKA Dept. of Internal Medicine II
Urogenital Cancer		
Prostata cancer	IMPROVE Studie: Importance of various supportive measures in the context of radical prostatectomy from the patient`s perspective Prospective questionnaire study to evaluate the importance of various supportive measures in the context of radical prostatectomy from the patient`s perspective.	UKA Dept. of Urology
Prostata cancer	PCO Studie: Prostate Cancer Outcomes Study The “Prostate Cancer Outcome” aims to contribute to improving the physical and mental health of men being treated for localised prostate cancer.	UKA Dept. of Urology
Prostata cancer	TRITON3 A multicenter, randomized, open-label phase 3 Study of Rucaparib versus physician's choice of therapy for patients with metastatic castration-resistant prostata cancer associated with homologous recombination deficiency.	Hematological oncological practice Heinrich, M.D./ Bangerter, M.D.
Prostata cancer	ADAM A randomized, open-label, Phase 2 Study of adjuvant Apalutamide or standard of care in subjects with high-risk, localized or locally advanced prostate cancer after radical prostatectom	UKA Dept. of Urology
Renal cell cancer	CARAT-Register Prospective presentation of the cross-sectoral treatment reality for patients with locally advanced, inoperable or metastatic renal cell carcinoma	UKA Dept. of Internal Medicine II

Renal cell cancer and/or Colon cancer	AAV-AH 01 Ex vivo identification of specific gene vector capsids for tumor-targeted gene therapy with adeno-associated viral vectors	UKA Dept. of Internal Medicine II
Renal cell carcinoma	CarboCare Prospective non-interventional study of Cabozantinib as monotherapy or in combination with Nivolumab in patients with advanced or metastatic renal cell carcinoma, under real-life clinical setting in 1st line treatment.	UKA Dept. of Urology
Urothelial cancer	Avenue Avelumab in real-world treatment of urothelial cancer – The AVENUE NIS	UKA Dept. of Urology
CNS-Tumors		
Glioblastoma	Intrago II A multicenter randomized phase III trial on Intraoperative Radiotherapy in newly diagnosed Glioblastoma multiforme (INTRAGO II)	UKA Dept. of Radiotherapy
Other Clinical Trials		
Metastatic solid tumors	ALPS Augsburg Longitudinal Plasma Study (ALPS) for the evaluation of Liquid Biopsy (LBx) as a tool for diagnostic support, detection of disease progression and for the identification of mutations in treatment settings of patients receiving palliative systemic treatment for solid neoplasia. Non-interventional study.	UKA Dept. of Internal Medicine II
NSCLC (neoadjuvant), SCLC (palliative), renal cell carcinoma (palliative), urothelial carcinoma (palliative)	EARLY Early analysis of response to immunotherapy using lymphocyte differentiation	UKA Dept. of Internal Medicine II
Radionuclide therapy	ZIS RNT Characterization of the cellular immune status in patients treated with radionuclide therapy	